Infliximab is a tumor necrosis factor TNF-α blocker and a chimeric monoclonal IgG1 antibody and it is used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and severe or disabling plaque psoriasis.
Cat.No
A012
Name
Infliximab
Chemical Properties
CAS
170277-31-3
Synonyms
pH value
Corresponds to reference standard： PASS
Non-reduced CE-SDS
98.5%
SEC-HPLC
99.4%
Isoelectric Point
Corresponds to reference standard:PASS
Bacterial Endotoxins Test
＜1 EU/ml
Residual Proteins of Host Cell
Exogenous Residual DNA
1 pg/mg
Residual protein A
＜1 ng/mg
Biological Activity
Compared with standard, the range of biological activity is 113%
Osmolality
Corresponds to reference standard: PASS
Peptide mapping
Corresponds to reference standard: PASS
N-terminal sequence
Corresponds to reference standard:PASS
References
[1]. Lucia A Méndez-García, et al. Infliximab ameliorates tumor necrosis factor-alpha-induced insulin resistance by attenuating PTP1B activation in 3T3L1 adipocytes in vitro. Scand J Immunol. 2018 Nov;88(5):e12716.
[2]. Isamu Yamakawa, et al. Inactivation of TNF-α ameliorates diabetic neuropathy in mice. Am J Physiol Endocrinol Metab. 2011 Nov;301(5):E844-52.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
